A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

Bernard M. Tijink, Jan Buter, Remco De Bree, Giuseppe Giaccone, Margreet S. Lang, Alexander Staab, C. René Leemans, Guus A.M.S. Van Dongen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review